This combined stem cell and gene therapy trial for ALS shows that CNS10-NPC-GDNF can be safely delivered to the lumbar spinal cord and produce GDNF for over 3 years with no negative effects on leg function, thus providing promise for patients with this relentless disease and no effective treatment. The gene discussed is GDNF; the disease is amyotrophic lateral sclerosis.